Novartis investigational lung cancer therapy grabs breakthrough status

The U.S. FDA has granted Breakthrough Therapy designation to Novartis ' capmatinib, which the drugmaker aims to file for approval later this year to treat a mutated form of lung cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news